A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology

A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology

Parkinson's disease (PD) is characterized by a progressive loss of dopaminergic neurons, linked to aggregation of alpha-synuclein (αSYN) into Lewy bodies. Current treatments are symptomatic and do not halt or reverse the neurodegeneration. Immunotherapy targeting aggregated αSYN shows potential...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dag Sehlin, Sahar Roshanbin, Olof Zachrisson, Martin Ingelsson, Stina Syvänen
Format:	Article
Language:	English
Published:	Elsevier 2025-03-01
Series:	Neurotherapeutics
Subjects:	Bispecific antibody Alpha-synuclein The blood-brain barrier Transferrin receptor mediated transcytosis Parkinson's disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S1878747924001971
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo
by: Gillian Bonvicini, et al.
Published: (2025-04-01)

High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose
by: Gillian Bonvicini, et al.
Published: (2025-08-01)

Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody
by: Eva Schlein, et al.
Published: (2024-12-01)

Alpha-Synuclein Dysregulation in Systemic Pathophysiology of Synucleinopathies
by: Hallie H. Dolin, et al.
Published: (2025-07-01)

Interactions of alpha-synuclein with membranes in Parkinson's disease: Mechanisms and therapeutic strategies
by: Baoyi Li, et al.
Published: (2024-10-01)

Toward alpha‐synuclein seed amplification assay in clinical practice
by: Mathieu Verdurand, et al.
Published: (2025-01-01)

Effect of hydrogen sulfide on alpha-synuclein aggregation and cell viability
by: Elena A. Ostrakhovitch, et al.
Published: (2025-05-01)

Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models
by: Sara Lucas-Del-Pozo, et al.
Published: (2025-10-01)

c-Abl Inhibitors in Parkinson’s: Exploring Hypotheses on Alpha-Synuclein Modulation
by: Jyutia Nargish, et al.
Published: (2025-04-01)

Engineered sequestrins inhibit aggregation of pathogenic alpha-synuclein mutants
by: Linnea Charlotta Hjelm, et al.
Published: (2025-05-01)

Seeding and transgenic overexpression of alpha‐synuclein triggers dendritic spine pathology in the neocortex
by: Sonja Blumenstock, et al.
Published: (2017-03-01)

Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD
by: A. R. Esteves, et al.
Published: (2011-01-01)

Alpha-Synuclein Effects on Mitochondrial Quality Control in Parkinson’s Disease
by: Lydia Shen, et al.
Published: (2024-12-01)

Neuropathological stages of neuronal, astrocytic and oligodendrocytic alpha-synuclein pathology in Parkinson’s disease
by: Maria Otero-Jimenez, et al.
Published: (2025-02-01)

Neuromodulation influences T lymphocyte calcium signaling and alpha synuclein clearance: implications for Parkinson’s disease
by: Alysia Ross, et al.
Published: (2025-07-01)

Phosphorylated alpha-synuclein distribution in the colonic enteric nervous system of patients with diverticular disease
by: François Cossais, et al.
Published: (2025-06-01)

Exploring the Potential of Biomimetic Peptides in Targeting Fibrillar and Filamentous Alpha-Synuclein—An In Silico and Experimental Approach to Parkinson’s Disease
by: Sophia A. Frantzeskos, et al.
Published: (2024-11-01)

Photochemically synthesized gold nanoparticles conjugated with Boswellic acid inhibit alpha synuclein aggregation and delay fibrillation kinetics
by: Masoumeh Gharb, et al.
Published: (2025-07-01)

Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform
by: Martin Schuler, et al.
Published: (2025-04-01)

Alpha-synuclein seeding amplification assays in Lewy body dementia: a brief review
by: Maria Bregendahl, et al.
Published: (2025-07-01)

Detection of hyperphosphorylated tau protein and &alpha;-synuclein in spinal cord of patients with Alzheimer&rsquo;s disease
by: Guo Y, et al.
Published: (2016-02-01)

Value of plasma alpha- and beta-synuclein levels in the diagnosis, severity, and functional outcome of acute ischemic stroke
by: Özge Başak Fırtına, et al.
Published: (2024-10-01)

N-acetylation of α-synuclein enhances synaptic vesicle clustering mediated by α-synuclein and lysophosphatidylcholine
by: Chuchu Wang, et al.
Published: (2024-12-01)

Templating of monomeric alpha-synuclein results in inflammation and SNpc dopamine neuron death in a genetic mouse model of induced synucleinopathy
by: Matthew D. Byrne, et al.
Published: (2025-07-01)

Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model
by: Fiona Weiss, et al.
Published: (2024-12-01)

Human induced pluripotent stem cell-derived dopaminergic neurons release alpha-synuclein through neuronal activity
by: Maierdanjiang Nuermaimaiti, et al.
Published: (2025-03-01)

Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood–brain barrier and interacts with amyloid β
by: Rebecca Faresjö, et al.
Published: (2024-12-01)

Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species
by: Mª Salomé Sirerol-Piquer, et al.
Published: (2025-03-01)

Pilot Study of [<sup>11</sup>C]HY-2-15: A Mixed Alpha-Synuclein and Tau PET Radiotracer
by: Chia-Ju Hsieh, et al.
Published: (2025-07-01)

Alpha-Synuclein Seed Amplification Assays in Parkinson’s Disease: A Systematic Review and Network Meta-Analysis
by: Jamir Pitton Rissardo, et al.
Published: (2025-06-01)

α-synuclein fibrils per se but not α-synuclein seeded aggregation causes mitochondrial dysfunction and cell death in human neurons
by: Plamena R. Angelova, et al.
Published: (2025-10-01)

Erythrocytic α-Synuclein in Parkinson’s Disease and Progressive Supranuclear Palsy—A Pilot Study
by: Costanza Maria Cristiani, et al.
Published: (2024-11-01)

Oligomeric alpha-synuclein causes early synaptic dysfunction of the corticostriatal pathway associated with non-motor symptoms
by: Laura Bellingacci, et al.
Published: (2025-07-01)

The interplay of iron, oxidative stress, and α-synuclein in Parkinson’s disease progression
by: Yan Chen, et al.
Published: (2025-04-01)

A novel stable transgenic zebrafish line expressing mCherry-tagged human alpha-synuclein in the nervous system and exhibiting all the key features of Lewy body disorders at larval stage
by: Silvia Zini, et al.
Published: (2025-09-01)

Parkinson’s Disease: A Narrative of the Evolving Understanding of the Role of α-Synuclein in Screening
by: Alan D. Kaye, et al.
Published: (2024-11-01)

Determinants of alpha-synuclein pathogenesis in Parkinson’s disease
by: Oriol Bárcenas, et al.
Published: (2026-04-01)

Alpha-synuclein in cutaneous small nerve fibers
by: Siepmann T, et al.
Published: (2016-10-01)

Imaging alpha-synuclein pathology in Parkinson’s disease
by: Ruiqing Ni
Published: (2026-04-01)

Differential expression of alpha-synuclein in hippocampal neurons.
by: Katsutoshi Taguchi, et al.
Published: (2014-01-01)